177 related articles for article (PubMed ID: 28852180)
21. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.
Levina E; Ji H; Chen M; Baig M; Oliver D; Ohouo P; Lim CU; Schools G; Carmack S; Ding Y; Broude EV; Roninson IB; Buttyan R; Shtutman M
Oncotarget; 2015 May; 6(15):13088-104. PubMed ID: 26036626
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor mediated epigenetic regulation of CRISP3 promoter in prostate cancer cells.
Pathak BR; Breed AA; Deshmukh P; Mahale SD
J Steroid Biochem Mol Biol; 2018 Jul; 181():20-27. PubMed ID: 29477539
[TBL] [Abstract][Full Text] [Related]
23. Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines.
Chakrabarti R; Robles LD; Gibson J; Muroski M
Cancer Genet Cytogenet; 2002 Dec; 139(2):115-25. PubMed ID: 12550771
[TBL] [Abstract][Full Text] [Related]
24. NCAPG2 promotes prostate cancer malignancy and stemness via STAT3/c-MYC signaling.
Zhang E; Chen Z; Liu W; Lin L; Wu L; Guan J; Wang J; Kong C; Bi J; Zhang M
J Transl Med; 2024 Jan; 22(1):12. PubMed ID: 38166947
[TBL] [Abstract][Full Text] [Related]
25. CUL4B/miR-33b/C-MYC axis promotes prostate cancer progression.
Zhao M; Qi M; Li X; Hu J; Zhang J; Jiao M; Bai X; Peng X; Han B
Prostate; 2019 Apr; 79(5):480-488. PubMed ID: 30609075
[TBL] [Abstract][Full Text] [Related]
26. MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity.
Whitlock NC; Trostel SY; Wilkinson S; Terrigino NT; Hennigan ST; Lake R; Carrabba NV; Atway R; Walton ED; Gryder BE; Capaldo BJ; Ye H; Sowalsky AG
Oncogene; 2020 Aug; 39(34):5663-5674. PubMed ID: 32681068
[TBL] [Abstract][Full Text] [Related]
27. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells.
De Leon JT; Iwai A; Feau C; Garcia Y; Balsiger HA; Storer CL; Suro RM; Garza KM; Lee S; Kim YS; Chen Y; Ning YM; Riggs DL; Fletterick RJ; Guy RK; Trepel JB; Neckers LM; Cox MB
Proc Natl Acad Sci U S A; 2011 Jul; 108(29):11878-83. PubMed ID: 21730179
[TBL] [Abstract][Full Text] [Related]
28. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
29. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction.
Li L; Ren C; Yang G; Fattah EA; Goltsov AA; Kim SM; Lee JS; Park S; Demayo FJ; Ittmann MM; Troncoso P; Thompson TC
Cancer Res; 2011 Dec; 71(24):7694-704. PubMed ID: 22025562
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of NF-kB decoy oligodeoxynucleotides in a prostate cancer cell line.
Fang Y; Sun H; Zhai J; Zhang Y; Yi S; Hao G; Wang T
Asian Pac J Cancer Prev; 2011; 12(10):2721-6. PubMed ID: 22320981
[TBL] [Abstract][Full Text] [Related]
31. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.
Chatterjee B
Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Targeting of the FKBP52 Co-Chaperone in Steroid Hormone Receptor-Regulated Physiology and Disease.
Guy NC; Garcia YA; Cox MB
Curr Mol Pharmacol; 2015; 9(2):109-25. PubMed ID: 25986565
[TBL] [Abstract][Full Text] [Related]
33. HUWE1 upregulation has tumor suppressive effect in human prostate cancer cell lines through c-Myc.
Qu H; Liu H; Jin Y; Cui Z; Han G
Biomed Pharmacother; 2018 Oct; 106():309-315. PubMed ID: 29966975
[TBL] [Abstract][Full Text] [Related]
34. Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia.
Grabowska MM; Kelly SM; Reese AL; Cates JM; Case TC; Zhang J; DeGraff DJ; Strand DW; Miller NL; Clark PE; Hayward SW; Gronostajski RM; Anderson PD; Matusik RJ
Endocrinology; 2016 Mar; 157(3):1094-109. PubMed ID: 26677878
[TBL] [Abstract][Full Text] [Related]
35. Placental growth factor gene expression in human prostate cancer and benign prostate hyperplasia.
Matsumoto K; Suzuki K; Koike H; Hasumi M; Matsui H; Okugi H; Shibata Y; Ito K; Yamanaka H
Anticancer Res; 2003; 23(5A):3767-73. PubMed ID: 14666676
[TBL] [Abstract][Full Text] [Related]
36. c-Myc-driven glycolysis via TXNIP suppression is dependent on glutaminase-MondoA axis in prostate cancer.
Qu X; Sun J; Zhang Y; Li J; Hu J; Li K; Gao L; Shen L
Biochem Biophys Res Commun; 2018 Oct; 504(2):415-421. PubMed ID: 30103944
[TBL] [Abstract][Full Text] [Related]
37. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues.
Zhao H; Ramos CF; Brooks JD; Peehl DM
J Cell Physiol; 2007 Jan; 210(1):111-21. PubMed ID: 17044071
[TBL] [Abstract][Full Text] [Related]
38. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
Sørensen KD; Borre M; Ørntoft TF; Dyrskjøt L; Tørring N
Int J Cancer; 2008 Feb; 122(3):509-19. PubMed ID: 17943724
[TBL] [Abstract][Full Text] [Related]
39. Correlation between androgen receptor expression and FGF8 mRNA levels in patients with prostate cancer and benign prostatic hypertrophy.
Wang Q; Stamp GW; Powell S; Abel P; Laniado M; Mahony C; Lalani EN; Waxman J
J Clin Pathol; 1999 Jan; 52(1):29-34. PubMed ID: 10343609
[TBL] [Abstract][Full Text] [Related]
40. Ezrin mediates c-Myc actions in prostate cancer cell invasion.
Chuan YC; Iglesias-Gato D; Fernandez-Perez L; Cedazo-Minguez A; Pang ST; Norstedt G; Pousette A; Flores-Morales A
Oncogene; 2010 Mar; 29(10):1531-42. PubMed ID: 20010876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
